Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
Milestone Pharmaceuticals CFO & EVP of Corp. Development Amit Hasija reported multiple equity transactions. On December 12, 2025, he acquired 100,000 common shares from a performance stock unit award that vested when the FDA issued a New Drug Application approval letter for Cardamyst (etripamil), and received an option for 100,000 shares at an exercise price of $1.74.
On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for tax liabilities. On January 26, 2026, 20,100 restricted stock units converted into common shares and 12,245 of those shares were sold at a weighted average price of $1.93, also to cover taxes. After these transactions, he directly held 99,848 common shares, 100,000 stock options, and 60,300 restricted stock units.
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported equity awards tied to FDA approval and routine tax-related sales. On December 12, 2025, he acquired 280,000 performance stock units and a matching 280,000-share stock option at $1.74, vesting in two equal tranches in 2026 after Cardamyst (etripamil) received a New Drug Application approval letter.
He also reported sell-to-cover sales of 133,054 common shares at $2.32 on December 15, 2025 and 34,523 shares at $1.93 on January 26, 2026, executed solely to cover income tax liabilities upon PSU and RSU vesting. On January 26, 2026, 66,600 RSUs converted into common shares as part of a four-year vesting schedule, leaving him with 482,744 common shares and 199,800 RSUs directly beneficially owned.
Milestone Pharmaceuticals Inc. filed a current report describing that it has issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray in the United States. The product is indicated for the management of paroxysmal supraventricular tachycardia, a type of rapid heart rhythm. The press release with additional details is included as Exhibit 99.1 and is incorporated by reference into the report.
Milestone Pharmaceuticals Inc. reported that it has closed a previously arranged royalty financing tied to its drug candidate etripamil. Under a Royalty Purchase Agreement originally signed in March 2023, funds managed by RTW Investments agreed to pay a purchase price of $75.0 million after U.S. Food and Drug Administration approval of etripamil, in exchange for a right to receive tiered quarterly royalties on annual net product sales of etripamil in the United States.
On January 12, 2026, the company completed this transaction and received the $75.0 million payment from certain funds managed by RTW in return for the royalty interest. Going forward, those RTW-managed funds are entitled to the specified tiered royalty stream on U.S. sales of etripamil, while Milestone retains the upfront cash proceeds from the sale.
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported pre‑planned stock sales under a Rule 10b5-1 trading plan. On January 7, 2026, he sold 500 common shares at $2.25 per share, and on January 8, 2026, he sold an additional 43,000 common shares at $2.25 per share. After these transactions, he directly beneficially owned 303,721 common shares.
The filing notes that the trading plan was adopted on September 30, 2025, which means the sales were scheduled in advance. The reported per-share price on January 8 is a weighted average; the shares were sold in multiple trades at prices ranging from $2.25 to $2.265.
A holder of Milestone Pharmaceuticals (MIST) common stock has filed a notice of intent to sell 79,500 shares through broker Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ. The filing lists an aggregate market value of $170,925.00 for this planned sale and notes that 85,169,344 common shares were outstanding.
The securities to be sold were acquired on November 16, 2018 by exercising stock options for cash. The notice also reports that over the past three months there was a separate 10b5-1 sale for Joseph Oliveto of 500 common shares, with gross proceeds of $1,125.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
A holder of MIST common stock filed a Form 144 notice to potentially sell 500 common shares through Morgan Stanley Smith Barney LLC on or about 01/07/2026 on NASDAQ. The planned sale has an aggregate market value of $1,025.00, compared with 85,169,000 common shares outstanding.
The 500 shares were acquired on 11/16/2018 from the issuer by exercising previously granted stock options and paying the purchase price in cash. By signing the notice, the person for whose account the securities may be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Milestone Pharmaceuticals Inc. reported that the European Medicines Agency has accepted its Marketing Authorization Application for etripamil nasal spray. This step means the European regulator has agreed to formally review the company’s request to market the drug.
The company noted that a decision on approval of etripamil nasal spray is expected by the first quarter of 2027, giving a clear timeline for when the European outcome should be known.
Milestone Pharmaceuticals Inc. reports that the U.S. Food and Drug Administration has approved its New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT).
The company also furnished a new corporate presentation dated December 15, 2025, which is available as an exhibit and through the Investors & Media section of its website. Milestone states that it intends to use this website section to provide material information in line with Regulation FD, alongside press releases, SEC filings, and public calls or webcasts.
Milestone Pharmaceuticals Inc.'s chief commercial officer reported an insider transaction involving the company's common shares.
On 12/09/2025, the officer disposed of 25,000 common shares in a transaction coded "G", which the filing explains is a bona fide gift made for no consideration to members of the reporting person's family who live outside the reporting person's household.
Following this gift, the reporting person directly beneficially owns 150,052 common shares of Milestone Pharmaceuticals.